Cellular uptake mechanisms of an antitumor ruthenium compound: The endosomal/lysosomal system as a target for anticancer metal-based drugs

Microscopy and Microanalysis

Volumn 19, Issue 5, 2013, Pages 1122-1130

  Côrte Real, Leonor ^a,d   Matos, António P ^b,c   Alho, Irina ^d   Morais, Tânia S ^c   Tomaz, Ana Isabel ^c   Garcia, Maria Helena ^c   Santos, Isabel ^a   Bicho, Manuel P ^d   Marques, Fernanda ^a  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b Universidade de Lisboa   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

antitumor activity; cellular uptake; cyclopentadienyl; endosomal system; intracellular distribution; lysosomes; Ruthenium(II)

Indexed keywords

ANTINEOPLASTIC AGENT; ETA5 CYCLOPENTADIENYL(2,2' BIPYRIDYL)(TRIPHENYLPHOSPHANE)RUTHENIUM(II); ETA5-CYCLOPENTADIENYL(2,2'-BIPYRIDYL)(TRIPHENYLPHOSPHANE)RUTHENIUM(II); ORGANOMETALLIC COMPOUND;

ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CHEMISTRY; CYTOPLASM; DOSE RESPONSE; DRUG EFFECT; ENDOSOME; HUMAN; LYSOSOME; METABOLISM; TEMPERATURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSOMES; HUMANS; LYSOSOMES; ORGANOMETALLIC COMPOUNDS; TEMPERATURE;

EID: 84884579362     PISSN: 14319276     EISSN: 14358115     Source Type: Journal    
DOI: 10.1017/S143192761300175X     Document Type: Article

References (36)

1. Bergamo, A., Gaiddon, C., Schellens, J.H., Beijnen, J.H. & Sava, G. (2012). Approaching tumour therapy beyond platinum drugs: Status of the art and perspectives of ruthenium drug candidates. J Inorg Biochem 106, 90-99.
2. Bosch, M.E., Sánchez, A.J., Rojas, F.S. & Ojeda, C.B. (2008). Analytical methodologies for the determination of cisplatin. J Pharm Biomed Anal 47, 451-459.
3. Bull, H., Murray, P.G., Thomas, D., Fraser, A.M. & Nelson, P.N. (2002). Acid phosphatases. Mol Pathol 55, 65-72.
4. C̃esen, M.H., Pegan, K., Spes, A. & Turk, B. (2012). Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 318, 1245-1251.
5. Crans, D.C., Smee, J.J., Gaidamauskas, E. & Yang, L. (2004). The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chem Rev 104, 849-902.
6. De Duve, C. (1983). Lysosomes revisited. Eur J Biochem 137, 391-397.
7. Egger, A.E., Rappel, C., Jakupec, M.A., Hartinger, C.G., Heffeter, P. & Keppler, B.K. (2009). Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J Anal At Spectrom 24, 51-61.
8. Galanski, M., Arion,V.B., Jakupec, M.A. & Keppler, B.K. (2003). Recent developments in the field of tumor-inhibiting metal complexes. Curr Pharm Des 9, 2078-2089.
9. Galanski, M.& Keppler, B.K. (2007). Searching for the magic bullet: Anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med Chem 7, 55-73.
10. Gallander, S.R. & Leonard, R.T. (1982). Effect of vanadate, molybdate and azide on membrane-associated ATPase and soluble phosphatase activities of corn roots. Plant Physiol 70, 1335-1340.
11. Gama, S.,Mendes, F., Esteves, T.,Marques, F.,Matos, A., Rino, J., Coimbra, J., Ravera, M., Gabano, E., Santos, I. & Paulo, A. (2012). Synthesis and biological studies of pyrazolyl-diamine Pt(II) complexes containing polyaromatic DNA-binding groups. Chembiochem 13, 2352-2362.
12. Garcia, M.H., Morais, T.S., Florindo, P., Piedade, M.F.M., Moreno, V., Ciudad, C. & Noe, V. (2009). Inhibition of cancer cell growth by ruthenium (II) cyclopentadienyl derivative complexes with heteroaromatic ligands. J Inorg Biochem 103, 354-361.
13. Groessl, M., Reisner, E., Hartinger, C.G., Eichinger, R., Semenova, O., Timerbaev, A.R., Jakupec, M.A., Arion, V.B. & Keppler, B.K. (2007). Structure-activity relationships for NAMIA-type complexes (HL)@trans-RuCl4L(S-dmso)ruthenate(III)# (L-imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): Aquation, redox properties, protein binding, and antiproliferative activity. J Med Chem 50, 2185-2193.
14. Hartinger, C.G., Jakupec, M.A., Zorbas-Seifried, S., Groessl, M., Egger, A., Berger,W., Zorbas, H., Dyson, P.J. & Keppler, B.K. (2008). KP1019, a new redox-active anticancer agentpreclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers 5, 2140-2155.
15. Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7, 573-584.
16. Levina, A., Mitra, A. & Lay, P.A. (2009). Recent developments in ruthenium anticancer drugs. Metallomics 1, 458-470.
17. Logan, R., Funk, R.S., Axcell, E. & Krise, J.P. (2012). Drugdrug interactions involving lysosomes: Mechanisms and potential clinical implications. Expert Opin Drug MetabToxicol 8, 943-958.
18. Marceau, F., Bawolak, M.T., Lodge, R., Bouthillier, J., Gagné-Henley, A., Gaudreault, R.C. & Morissette, G. (2012). Cation trapping by cellular acidic compartments: Beyond the concept of lysosomotropic drugs. Toxicol App Pharmacol 259, 1-12.
19. Morais, T.S., Santos, F., Côrte-Real, L., Marques, F., Robalo, M.P., Madeira, P.J.A. & Garcia, M.H. (2013). Biological activity and cellular uptake of @Ru(h5-C5H5)(PPh3)(Me2bpy)#@CF3SO3# complex. J Inorg Biochem 122, 8-17.
20. Morais, T.S., Silva, T.J.,Marques, F., Robalo,M.P., Avecilla, F., Amorim, M.P.J., Mendes, P.J., Santos, I. & Garcia, M.H. (2012). Synthesis of organometallic ruthenium(II) complexes with strong activity against several human cancer cell lines. J Inorg Biochem 114, 65-74.
21. Moreno, V., Lorenzo, J., Aviles, F.X., Garcia, M.H., Ribeiro, J.P., Morais, T.S., Florindo, P. & Robalo, M.P. (2010). Studies of the antiproliferative activity of ruthenium (II) cyclopentadienyl-derived complexes with nitrogen coordinated ligands. Bioinorg Chem Appl 2010, 936834, doi:10.1155/2010/ 936834.
22. Ndolo, R.A., Jacobs, D.T., Forrest, M.L. & Krise, J.P. (2010). Intracellular distribution-based anticancer drug targeting: Exploiting a lysosomal acidification defect associated with cancer cells.Mol Cell Pharmacol 2, 131-136.
23. Olmos, E. & Hellin, E. (1997). Cytochemical localization of ATPase plasma membrane and acid phosphatase by ceriumbased method in a salt-adapted cell line of Pisumsativum. J Exp Bot 48, 1529-1535.
24. Pessoa, J.C. & Tomaz, I. (2010). Transport of therapeutic vanadium and ruthenium complexes by blood plasma components. Curr Med Chem 17, 3701-3738.
25. Puckett, C.A., Ernst, R.J. & Barton, J.K. (2010). Exploring the cellular accumulation of metal complexes. Dalton Trans 39, 1159-1170.
26. Record, R.D. & Griffing, L.R. (1988). Convergence of the endocytic and lysosomal pathways in soybean protoplasts. Planta 176, 425-432.
27. Romero-Canelón, I., Pizarro, A.M., Habtemariam, A. & Sadler, P.J. (2012). Contrasting cellular uptake pathways for chlorido and iodidoiminopyridine ruthenium arene anticancer complexes. Metallomics 4, 1271-1279.
28. Spinner, D.M. (2001). MTT growth assays in ovarian cancer. Methods Mol Med 39, 175-177.
29. Tarragó-Trani, M.T. & Storrie, B. (2007). Alternate routes for drug delivery to the cell interior: Pathways to the Golgi apparatus and endoplasmic reticulum.Adv Drug Deliv Rev 59, 782-797.
30. Timerbaev, A.R., Hartinger, C.G., Aleksenko, S.S. & Keppler, B.K. (2006). Interactions of antitumor metallodrugs with serum proteins: Advances in characterization using modern analytical methodology. Chem Rev 106, 2224-2248.
31. Tomaz, A.I., Jakusch, T.,Morais, T.S.,Marques, F., De Almeida, R.F.,Mendes, F., Enyedy, E.A., Santos, I., Pessoa, J.C., Kiss, T. & Garcia, M.H. (2012a). RuII(h5-C5H5)(bipy)(PPh3)#-, a promising large spectrum antitumor agent: Cytotoxic activity and interaction with human serum albumin. J Inorg Biochem 117, 261-269.
32. Tomaz, A.I., Jakusch, T.,Morais, T.S.,Marques, F., De Almeida, R.F.,Mendes, F., Enyedy, E.A., Santos, I., Pessoa, J.C., Kiss, T. & Garcia, M.H. (2012b). Patent application PT105890/PPI-46249, 2011.
33. Wlodkowic, D., Skommer, J., McGuinness, D., Hillier, C. & Darzynkiewicz, Z.L. (2009). ER-golgi network-A future target for anti-cancer therapy. Leuk Res 33, 1440-1447.
34. World Health Organization (2013). Cancer Fact Sheet No. 297. Available at: Http://www.who.int/mediacentre/factsheets/fs297/en//index.html (accessed October 20, 2012
35. Yang, T.T., Sinai, P. & Kain, S.R. (1996). An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells. Anal Biochem 241, 103-108.
36. Zhao, G. & Lin, H. (2005). Metal complexes with aromatic N-containing ligands as potential agents in cancer treatment. Curr Med Chem Anticancer Agents 5, 137-147.